---
title: Publication of NT-proBNP patent application
description: "Patent application: highly sensitive particle enhanced assay for the quantification of NT-proBNP
published by the World Intellectual Property Organization"
---

 

Moss, 18 February 2021

Gentian Diagnostics AS today announces that its patent application for a highly sensitive particle enhanced assay for the quantification of NT-proBNP has been published by the World Intellectual Property Organization (PCT Application No. PCT/EP2020/072720) with WIPO number: WO2021/028520. The technology described in this patent application enables Gentian to develop and commercialize anautomated and fast NT-proBNP assay for open turbidimetric clinical chemistry  
platforms.

The launch of the NT-proBNP assay, a biomarker to aid in the diagnosis of congestive heart failure (CHF), is planned for 4Q 2021. The assay under development by Gentian Diagnostics will enable improvement of laboratory productivity based on higher throughput in comparison to currently used assays and contribute to the harmonization and standardization of the NT-proBNP assays.

Going forward, the Company will announce when patents are granted.

For further information, please contact:  
Hilja Ibert  
CEO, Gentian Diagnostics  
E-mail: [hilja.ibert@gentian.no](mailto:hilja.ibert@gentian.no)    
Cell Phone: +47 919 05 242

Njaal Kind  
CFO, Gentian Diagnostics  
E-mail: [njaal.kind@gentian.no](mailto:njaal.kind@gentian.no)   
Cell Phone. +47 919 06 525

[Access the news on Oslo Bors NewsWeb site](https://newsweb.oslobors.no/message/525326)

### You may also read

[Jul 02, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/nt-probnp-patent#)

##### [Gentian Diagnostics: Invitation to presentation of second quarter results](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-invitation-to-presentation-of-second-quarter-results-1)

Gentian Diagnostics ASA will present its second quarter 2026 results on 9 July 2026 at 09.00 CEST. The..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-invitation-to-presentation-of-second-quarter-results-1)

[Jun 24, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/nt-probnp-patent#)

##### [ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT](https://www.gentian.com/investor-relations-stock-information/investors-news/essange-reagents-and-gentian-diagnostics-announce-collaboration-agreement)

Amsterdam / Moss, 24 June 2026 ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/essange-reagents-and-gentian-diagnostics-announce-collaboration-agreement)

[May 29, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/nt-probnp-patent#)

##### [Mandatory notification of trade](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1780055230560)

Moss, 29 May 2026 Gentian Diagnostics ASA ("Gentian") has today been notified that the following transaction..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1780055230560)